http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009062160-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e40b72d3182e6d250ae337e3838fa842 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5bd2652a0dd9db87680fabb91b842b76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7d241434dd2e686fcc5aab7061164f8c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb9c6b40161bafe7bd55f0b4defcea04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aa2906f3850d51368c0f33e5a74f7550 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9ee135a8ab4c7df55b4922593f93caa8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-523 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-245 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6863 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 |
| filingDate | 2008-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2a06f051adb2c7f6f442d5ed14f00c5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_575c3dccc141a17912a8b2f5d7861c32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dddc7cfabdd32e1bb61ff43dc49c5ef9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc7c5634becb4a30a04a7be1d1ff80e3 |
| publicationDate | 2009-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2009062160-A2 |
| titleOfInvention | Rantes levels as a diagnostic and therapeutic for acute graft versus host disease |
| abstract | Disclosed herein are methods for determining the likelihood of a subject to develop Acute graft versus host disease (aGVHD) upon receiving myeloablative allogeneic hematopoietic stem cell transplantation (HSCT). One such method comprises assaying for baseline plasma concentration of RANTES in a sample obtained from the subject, and comparing the baseline plasma concentration of RANTES to a predetermined level. The method may further comprise assaying for day 7 plasma concentration of RANTES in sample obtained from the subject, and comparing the day 7 plasma concentration of RANTES to a predetermined level. Another such method comprises assaying for day 7 plasma concentration of RANTES in a sample obtained from the subject, and comparing the day 7 plasma concentration of RANTES to a predetermined level. Another such method comprises assaying for donor plasma concentration of RANTES in a sample obtained from a donor of the hemtopoietic stem cells, and comparing the donor plasma concentration of RANTES to a predetermined level, wherein a donor plasma concentration of RANTES less than the predetermined level indicates a likelihood of the subject to develop aGVHD upon receiving myeloablative allogeneic HSCT from that donor. Other methods include assaying for day 0, or for day 7, plasma concentration of MCP-1 in a sample obtained from the subject, and comparing the day 0 or day 7, plasma concentration of MCP-1 to a predetermined level. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014079946-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10151745-B2 |
| priorityDate | 2007-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 324.